Treats chronic graft-versus-host disease (chronic GVHD) after failure of at least two…. Sold as Rezurock. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Belumosudil Mesylate (sold as Rezurock), first approved Jul 16, 2021, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Rezurock | Part D | $309M | +27% | 1,672 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaMultiple Myeloma · M.D. Anderson Cancer Center | Phase 1 / Phase 2 | Recruiting | Oct 27, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 16, 2021 | RezurockNDA 214783 · New molecular entity | Kadmon Pharms LLC | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
